Mar. 26 at 7:05 PM
$SLS $ABBV Phase 3 Registrational results are coming, and will give Gps the FDA Green Light to treat 100,000 AML Patients Currently in Remission.
XCCo estimated
$280K Rev Per Patient in Year 1.
$28B Total Addressable Market - right out of the Gate, worth
$40B to Big Pharma.
This
$5 stock will be
$50 the Instant the P3 Results are Announced, and climbing.
All P3 Patients were enrolled 24 + months ago, Phase 3 Results are Coming, - conceivably could be ANY DAY NOW.
The Future is Inevitable.